{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"groups":[{"description":"Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.\n\ncyproheptadine hydrochloride: Given orally","id":"OG000","title":"Arm I Cyproheptadine Hydrochloride"},{"description":"Patients receive an oral placebo twice daily for 8 weeks.\n\nplacebo: Given orally","id":"OG001","title":"Arm II Placebo"}],"paramType":"NUMBER","populationDescription":"LOCF","reportingStatus":"POSTED","timeFrame":"8 weeks","title":"Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline","type":"PRIMARY","unitOfMeasure":"participants"}